Evidence map›Paper›PMID 32577638›Full record

ArticlebioRxiv : the preprint server for biology2020

Effective Inhibition of SARS-CoV-2 Entry by Heparin and Enoxaparin Derivatives.

Ritesh Tandon, Joshua S Sharp, Fuming Zhang, Vitor H Pomin, Nicole M Ashpole, Dipanwita Mitra, Weihua Jin, Hao Liu, Poonam Sharma, Robert J Linhardt

Registry-linked trialOpen access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04490239 (Intranasal Heparin Tolerability Study), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04490239 early_phase1completednot on this map

Intranasal Heparin Tolerability Study

TypeinterventionalSponsorJoshua SharpRan2020 to 2020Enrolled6ConditionsCovid19ArmsIntranasal heparin sodium (porcine)
3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 72 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Ritesh TandonDepartment of Microbiology and Immunology, University of Mississippi Medical Center, Jackson, MS 39216.
Joshua S SharpDepartment of BioMolecular Sciences, University of Mississippi, Oxford, MS 38677.
Fuming ZhangCenter for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY, 12180.
Vitor H PominDepartment of BioMolecular Sciences, University of Mississippi, Oxford, MS 38677.
Nicole M AshpoleDepartment of BioMolecular Sciences, University of Mississippi, Oxford, MS 38677.
Dipanwita MitraDepartment of Microbiology and Immunology, University of Mississippi Medical Center, Jackson, MS 39216.
Weihua JinCenter for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY, 12180.
Hao LiuDepartment of BioMolecular Sciences, University of Mississippi, Oxford, MS 38677.
Poonam SharmaDepartment of Microbiology and Immunology, University of Mississippi Medical Center, Jackson, MS 39216.
Robert J LinhardtCenter for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY, 12180.
University of Mississippi · USRensselaer Polytechnic Institute · USUniversity of Mississippi Medical Center · US

Funding

Pilot Project ProgramP30GM122733 · NIGMS · UNIVERSITY OF MISSISSIPPI · PI WILLETT, KRISTINE L · 2018 to 2022
$5.3M
Molecular Structure Determination by Mass Spectrometry and Computational ModelingR01GM127267 · NIGMS · UNIVERSITY OF MISSISSIPPI · PI Joshua S Sharp · 2018 to 2026
$3.8M
NIGMS NIH HHS P30 GM122733NIGMS NIH HHS R01 GM127267
6 · The paper itself

Abstract

Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) has caused a pandemic of historic proportions and continues to spread globally, with enormous consequences to human health. Currently there is no vaccine, effective therapeutic or prophylactic. Like other betacoronaviruses, attachment and entry of SARS-CoV-2 is mediated by the spike glycoprotein (SGP). In addition to its well-documented interaction with its receptor, human angiotensin converting enzyme 2 (hACE2), SGP has been found to bind to glycosaminoglycans like heparan sulfate, which is found on the surface of virtually all mammalian cells. Here, we pseudotyped SARS-CoV-2 SGP on a third generation lentiviral (pLV) vector and tested the impact of various sulfated polysaccharides on transduction efficiency in mammalian cells. The pLV vector pseudotyped SGP efficiently and produced high titers on HEK293T cells. Various sulfated polysaccharides potently neutralized pLV-S pseudotyped virus with clear structure-based differences in anti-viral activity and affinity to SGP. Concentration-response curves showed that pLV-S particles were efficiently neutralized by a range of concentrations of unfractionated heparin (UFH), enoxaparin, 6-

Indexed as

CoronavirusCOVID-19GlycosaminoglycansPseudotypingSpike glycoprotein

Identifiers

PMID32577638
PMCPMC7302190
OpenAlexW3033171357

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.